<DOC>
	<DOC>NCT01124565</DOC>
	<brief_summary>This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.</brief_summary>
	<brief_title>Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults</brief_title>
	<detailed_description>Revance is conducting this Phase 2 clinical study to establish the safety of two (2) sequential doses of RT001 Topical Gel at Baseline (Day 0) and Week 4 for the treatment of moderate to severe LCLs at rest.</detailed_description>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<criteria>Written informed consent including authorization to release health information Female or male, 18 to 65 years of age and in good general health Willing and able to follow study instructions and likely to complete all study requirements Moderate to severe lateral canthal lines (crow's feet wrinkles) Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as LambertEaton syndrome and myasthenia gravis Muscle weakness or paralysis, particularly in the area receiving study treatment Active disease or irritation at the treatment areas including the eye and the skin Pregnant, nursing, or planning a pregnancy during the study; or is a woman of child bearing potential (WOCBP) but is not willing to use an effective method of birth control Previous participation in a RT001 clinical study Previous treatment with botulinum toxin (any serotype)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Lateral Canthal Lines</keyword>
	<keyword>Crow's Feet</keyword>
	<keyword>Facial Wrinkles</keyword>
</DOC>